From The “Things I’d Prefer Not To Think About” Files: The Daughter’s Breast Milk

Georgia on the right, her two patrons on the left…

An ABC News story from 2009 turned up on my ethics radar.

Tim Browne, a retired teacher and musician from Wiltshire, England, was diagnosed with colon cancer. He was operated on a week before his daughter’s wedding, but  the cancer had spread to his liver and lymph nodes. Doctors said it was terminal.

While he was undergoing chemotherapy, his daughter suggested an unconventional treatment: her breast milk. She had seen a TV report about an American man who had  made a miraculous recovery from prostate cancer by drinking it. Soon Tim was having his morning cereal with daughter Georgia’s milk.

Georgia was nursing her 8-month-old son Monty and offered to set aside a few ounces of milk every day for Browne. Browne started calling Monty his “milk brother.” “If I have a lactating daughter, why not take advantage of her? As long as Monty didn’t mind,” Browne said.

There’s no evidence that breast milk really does treat cancer, but doctors said that as long as Browne believed it did, the succor might have a genuine placebo effect.

What do we properly call a father consuming his daughter’s breast milk? Is that too close to incest for comfort?Does it matter if it’s close, as long as it isn’t quite? Continue reading

Ethics and the $1000 a Day Drug

Yesterday, The New York Times  informed us that a small drug company called Allos is charging $30,000 a month for a cancer drug, Folotyn, that treats a rare and usually fatal form of cancer that strikes fewer that 6,000 American a year. It doesn’t cure the cancer, but merely slows it down; even with that, victims seldom survive more than a few months. “This drug is not a home run. It’s not even a double. It’s a single,” the Times quotes Dr. Brad S. Kahl, a lymphoma specialist at the University of Wisconsin, as saying. Continue reading